Literature DB >> 24837568

Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice.

Aviva Katzav1, Tal Ben-Ziv2, Miri Blank2, Chaim G Pick3, Yehuda Shoenfeld4, Joab Chapman5.   

Abstract

This study compares the effects of human antiphospholipid (aPL) and anti-P-ribosomal (anti-P) IgG and control IgG on the brain. Intracerebroventricular (ICV) injected aPL mice (exAPS) displayed specific hyperactivity compared to anti-P-injected (exSLE) and control mice. In contrast ICV injected anti-P-injected mice specifically displayed depression-like behavior and olfactory impairment compared to the other 2 groups. Both anti-P and aPL injected mice were impaired in the passive avoidance test compared to controls. The distinct cognitive effects of the 2 pathogenic antibodies argue for a specific and differential direct action of these autoantibodies on the brain in clinical disease.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoantibodies; Behavior; Cognitive function; Depression; Experimental mouse model; Smell

Mesh:

Substances:

Year:  2014        PMID: 24837568     DOI: 10.1016/j.jneuroim.2014.04.003

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

1.  The olfactory function is impaired in patients with idiopathic inflammatory myopathies.

Authors:  L Iaccarino; N Shoenfeld; M Rampudda; M Zen; M Gatto; A Ghirardello; N Bassi; L Punzi; Y Shoenfeld; A Doria
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

Review 3.  Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials.

Authors:  Nina Kello; Erik Anderson; Betty Diamond
Journal:  Arthritis Rheumatol       Date:  2019-08-07       Impact factor: 10.995

Review 4.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

5.  Olfactory impairment in patients with the fibromyalgia syndrome and systemic sclerosis.

Authors:  Howard Amital; Nancy Agmon-Levin; Netta Shoenfeld; Yoav Arnson; Daniela Amital; Pnina Langevitz; Alexandra Balbir Gurman; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

6.  Evaluation of peripheral olfactory pathways in chronic autoimmune thyroiditis.

Authors:  Mikail Inal; Neşe Asal; Irfan Karahan; Aşkın Güngüneş; Şenay Arıkan Durmaz
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-18       Impact factor: 3.236

7.  Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome.

Authors:  R Weiss; A Bitton; L Nahary; M T Arango; I Benhar; M Blank; Y Shoenfeld; J Chapman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

8.  Lupus anti-ribosomal P autoantibody proteomes express convergent biclonal signatures.

Authors:  M A Al Kindi; A D Colella; D Beroukas; T K Chataway; T P Gordon
Journal:  Clin Exp Immunol       Date:  2016-01-29       Impact factor: 4.330

Review 9.  Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus.

Authors:  Maria Gerosa; Barbara Poletti; Francesca Pregnolato; Gabriella Castellino; Annalisa Lafronza; Vincenzo Silani; Piersandro Riboldi; Pier Luigi Meroni; Joan T Merrill
Journal:  Front Immunol       Date:  2016-02-01       Impact factor: 7.561

10.  Depressive and Anxiety Disorders in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations.

Authors:  Ru Bai; Shuang Liu; Yueyin Zhao; Yuqi Cheng; Shu Li; Aiyun Lai; Zhongqi Xie; Xinyu Xu; Zhaoping Lu; Jian Xu
Journal:  J Immunol Res       Date:  2016-09-26       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.